CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial
2021 · Nature Medicine · 545 citations
https://doi.org/10.1038/s41591-021-01436-0
S
Surbhi Sidana
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
409
Papers
7.1K
Citations
37
h-index
105
i10-index
Surbhi Sidana is an academic researcher from Palo Alto University. The author has contributed to research in topics: Multiple Myeloma Research and Treatments & CAR-T cell therapy research & Amyloidosis: Diagnosis, Treatment, Outcomes. The author has an h-index of 37, co-authored 348 publications.
ORCID: 0000-0003-3288-7614Papers by this author
worksTreatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group
2021 · The Lancet Oncology · 257 citations
https://doi.org/10.1016/s1470-2045(20)30756-7
Allogeneic BCMA-targeting CAR T cells in relapsed/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results
2023 · Nature Medicine · 227 citations
https://doi.org/10.1038/s41591-022-02182-7
Immune reconstitution and infectious complications following axicabtagene ciloleucel therapy for large B-cell lymphoma
2021 · Blood Advances · 179 citations
https://doi.org/10.1182/bloodadvances.2020002732
Universal: An Allogeneic First-in-Human Study of the Anti-Bcma ALLO-715 and the Anti-CD52 ALLO-647 in Relapsed/Refractory Multiple Myeloma
2020 · Blood · 71 citations
https://doi.org/10.1182/blood-2020-140641
CD22-directed CAR T-cell therapy for large B-cell lymphomas progressing after CD19-directed CAR T-cell therapy: a dose-finding phase 1 study
2024 · The Lancet · 47 citations
https://doi.org/10.1016/s0140-6736(24)00746-3
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat